**Study Title:** Treatment Trial for Patients with Skin Cancer

**Scientific Title:** ECOG E2607 - Phase II Study of Dasatinib in Patients With Unresectable Locally Advanced or Metastatic Mucosal, Acral, or Solar Melanoma

**Department and/or Specialty:** Oncology – Skin Cancer

**Investigator:** Michael Thompson, MD, PhD

**Contact Information:** Chanda Miller

**Purpose:**

Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

This phase II trial is studying how well dasatinib works in treating patients with locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery.

**Treatment/Intervention:**

Patients will receive dasatinib by mouth twice a day. Treatment may continue for as long as benefit is shown.

After finishing treatment, patients will be evaluated periodically for up to 5 years.